NCT05851755

Brief Summary

LUCENT is an observational study focused on malignant pulmonary and tracheo-bronchial disease. It involves a large proportion of reference Italian thoracic surgery centers. The relevance of the study is related to the epidemiology of lung cancer in the world - also known as "Big Killer" - and the high mortality rates both in males and females. The aim of his prospective study is to collect a large bulk of postoperative patients' outcome data and to produce up-to-date descriptive statistics of patients undergoing surgery for lung cancer. These results will be pivotal to compare the clinical results of all the relevant specialities involved in the care of lung cancer such as medical oncologists and radiation oncologists.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
23mo left

Started Apr 2023

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress62%
Apr 2023Mar 2028

Study Start

First participant enrolled

April 1, 2023

Completed
29 days until next milestone

First Submitted

Initial submission to the registry

April 30, 2023

Completed
10 days until next milestone

First Posted

Study publicly available on registry

May 10, 2023

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2028

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2028

Last Updated

May 10, 2023

Status Verified

April 1, 2023

Enrollment Period

5 years

First QC Date

April 30, 2023

Last Update Submit

April 30, 2023

Conditions

Lung Cancer

Outcome Measures

Primary Outcomes (1)

  • Lung cancer surgery outcomes

    Benchmarking national outcome data of the treatment of lung cancer

    5 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

PaTientsin with lung cancer and an indication for respective surgery

You may qualify if:

  • Patients with lung cancer
  • informed consent

You may not qualify if:

  • alcohol or drug abuse
  • age \< 18
  • inability to express consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of L'Aquila

L’Aquila, 67100, Italy

Location

Related Publications (1)

  • Bertolaccini L, Ciani O, Lucchi M, Zaraca F, Bertani A, Crisci R, Spaggiari L; LUCENT Study Group. Outcomes of Patients With Early and Locally Advanced Lung Cancer: Protocol for the Italian Lung Cancer Observational Study (LUCENT). JMIR Res Protoc. 2024 Oct 8;13:e57183. doi: 10.2196/57183.

    PMID: 39378423DERIVED

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Roberto Crisci, MD

    University of Aquila

    PRINCIPAL INVESTIGATOR

  • Luca Bertolaccini, MD

    European Institute of Oncology

    PRINCIPAL INVESTIGATOR

  • Alessandro Bertani, MD

    IRCCS ISMETT -UPMC ITALY

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 30, 2023

First Posted

May 10, 2023

Study Start

April 1, 2023

Primary Completion (Estimated)

March 31, 2028

Study Completion (Estimated)

March 31, 2028

Last Updated

May 10, 2023

Record last verified: 2023-04

Locations

IT(1)